QR Kod

Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation

Background: At the time of publication of the most recent National Institute for Health and Care Excellence (NICE) guidance [technology appraisal (TA) 32] in 2002 on beta-interferon (IFN-β) and glatiramer acetate (GA) for multiple sclerosis, there was insufficient evidence of their clinical effectiv...

Ful tanımlama

Kaydedildi:
Asıl Yazarlar: GJ Melendez-Torres, Peter Auguste, Xavier Armoiry, Hendramoorthy Maheswaran, Rachel Court, Jason Madan, Alan Kan, Stephanie Lin, Carl Counsell, Jacoby Patterson, Jeremy Rodrigues, Olga Ciccarelli, Hannah Fraser, Aileen Clarke
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: NIHR Journals Library 2017-09-01
Seri Bilgileri:Health Technology Assessment
Konular:
multiple sclerosis
clinically isolated syndrome
beta interferon
glatiramer acetate
systematic review
economic evaluation
Online Erişim:https://doi.org/10.3310/hta21520
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller